Downstream versus upstream P2Y12 blocker strategy in NSTE-ACS with invasive indication

Phase 4, randomised, open-label trial of ticagrelor, prasugrel, Hepalin-M and bivalirudin in acute coronary syndrome (ACS), non–ST-segment elevation acute coronary syndrome (NSTE-ACS), Non-ST-segment elevation myocardial infarction (NSTEMI) and 1 more (4 arms), sponsored by Azienda Ospedaliero-Universitaria di Padova. Primary endpoints: Net adverse cardiac events at 30 days and Net adverse cardiac events at 12 months. Started Sep 2021; status: terminated.